三元基因(837344) - 2022 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter of 2022 was CNY 29,687,302.57, down 13.12% year-on-year[16] - Net profit attributable to shareholders for the first quarter of 2022 was CNY 3,351,979.41, an increase of 18.72% compared to the same period last year[16] - Basic earnings per share for the first quarter of 2022 were CNY 0.03, up 50.00% from CNY 0.02 in the previous year[16] - Total operating revenue for Q1 2022 was ¥29,687,302.57, a decrease of 13.5% from ¥34,171,109.14 in Q1 2021[43] - Net profit for Q1 2022 increased to ¥3,351,979.41, representing a growth of 18.7% compared to ¥2,823,376.49 in Q1 2021[45] - Operating profit for Q1 2022 was ¥3,908,239.93, an increase from ¥3,238,899.40 in Q1 2021[44] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 633,768,796.90, a decrease of 2.54% compared to the end of the previous year[16] - The company's total liabilities to total assets ratio was 13.77% as of March 31, 2022, down from 16.47% at the end of the previous year[16] - Total liabilities decreased to CNY 87,245,865.14 from CNY 107,102,826.23, a reduction of 18.6%[37] - Total equity increased to CNY 546,522,931.76, up from CNY 543,170,952.35, reflecting a growth of 0.6%[37] - The total assets decreased to ¥655,806,914.15 from ¥671,514,340.21[41] - Total liabilities decreased to ¥87,239,467.94 in the latest reporting period, down from ¥106,268,831.41[41] Cash Flow - Net cash flow from operating activities increased by CNY 17,055,940.04, representing a growth of 592.80% compared to the previous year[17] - Cash inflows from operating activities reached CNY 56,961,110.72, up from CNY 42,777,401.41 year-over-year[50] - The net cash flow from operating activities was CNY 14,178,778.03, a recovery from a negative CNY 2,877,162.01 in the previous year[52] - The company reported a net cash outflow from financing activities of CNY 1,233,195.61, an improvement from negative CNY 7,546,414.36 last year[52] - The company experienced a net decrease in cash and cash equivalents of CNY 28,713,615.61, compared to a decrease of CNY 19,798,432.64 in the previous year[55] Shareholder Information - The registered capital of the company is CNY 121,810,000[14] - The total number of ordinary shareholders is 7,623[20] - The largest shareholder, Beijing Southeast Medicine Investment Holding Co., Ltd., holds 46,907,925 shares, representing 38.51% of total shares[22] - Zhejiang Shengda Technology Development Co., Ltd. is the second largest shareholder with 17,199,373 shares, accounting for 14.12%[22] - The total shares held by the top ten shareholders amount to 90,000,950, which is 73.89% of the total shares[22] Research and Development - The company is conducting a Phase III clinical trial for a drug targeting respiratory syncytial virus, with 190 subjects enrolled as of January 18, 2022[31] - The company has completed the first interim analysis of the clinical trial, with positive efficacy trends and good safety observed[31] - Research and development expenses decreased to ¥2,123,768.92 in Q1 2022, down 53.8% from ¥4,592,697.23 in Q1 2021[44] Compliance and Commitments - The company has complied with all commitments made during its public offering process, with no breaches reported[27] - The company has no ongoing litigation, external guarantees, or external loans during the reporting period[26] - The company has no profit distribution or capital increase from reserves during the reporting period[32] Asset Management - The company has pledged assets totaling 76,309,892.76 yuan, which represents 12.04% of total assets[29] - Current assets totaled CNY 360,672,150.71, a decrease of 10.5% from CNY 403,029,145.30 as of December 31, 2021[35] - Accounts receivable decreased to CNY 74,656,756.47 from CNY 90,665,072.86, representing a decline of 17.7%[35] - Inventory increased to CNY 25,894,154.27, up 27.0% from CNY 20,343,948.52[35] - Total non-current assets rose to CNY 273,096,646.19, an increase of 10.4% from CNY 247,244,633.28[36] - Cash and cash equivalents were CNY 245,884,230.48, down from CNY 274,215,710.45, a decrease of 10.3%[35]